H.C. Wainwright Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating
Pyxis Oncology GAAP EPS of -$0.29
Express News | Pyxis Oncology Inc: Expected Cash Runway Into 2H 2026
Pyxis Oncology | 10-Q: Q2 2024 Earnings Report
Express News | Pyxis Oncology Provides Corporate Update and Reports Financial Results for Second Quarter 2024
Express News | Pyxis Oncology Q2 Net Income USD -17.301 Million Vs. IBES Estimate USD -18.8 Million
Express News | Pyxis Oncology Q2 Income From Operations USD -20.032 Million Vs. IBES Estimate USD -20.9 Million
Express News | Pyxis Oncology Q2 Basic EPS USD -0.29
Pyxis Oncology Draws Buy at Stifel on Lead Asset
Pyxis Oncology Price Target Announced at $10.00/Share by Stifel
Pyxis Oncology Initiated at Buy by Stifel
RBC Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $7
Analysts Have Conflicting Sentiments on These Healthcare Companies: Morphic Holding (MORF), Pyxis Oncology (PYXS) and Zynex (ZYXI)
Institutional Owners May Ignore Pyxis Oncology, Inc.'s (NASDAQ:PYXS) Recent US$25m Market Cap Decline as Longer-term Profits Stay in the Green
Express News | Pyxis Oncology Expands Board of Directors With Appointment of Michael a. Metzger
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Hims & Hers Health (HIMS) and Cytokinetics (CYTK)
Pyxis Oncology | 10-Q: Q1 2024 Earnings Report
Pyxis Oncology 1Q Research and Development Expenses $13.0M >PYXS
Pyxis Oncology 1Q Loss/Shr 6c >PYXS